References

Hepatocellular carcinoma

10.1016/s0140-6736(22)01200-4 · 2022 · External reference

Global cancer statistics 2020: GLOBOCAN estimates of in-cidence and mortality worldwide for 36 cancers in 185 countries

10.3322/caac.21660 · 2021 · External reference

Cancer statistics, 2022

10.3322/caac.21708 · 2022 · External reference

Advancing precision medicine in hepato-cellular carcinoma: current challenges and future directions in liquid biopsy, immune mi-croenvironment, single nucleotide polymorphisms, and conversion therapy

10.1080/20450923.2025.2493457 · 2025 · External reference

RNA in cancer

10.1038/s41568-020-00306-0 · 2021 · External reference

Cancer epigenomics: beyond genomics

10.1016/j.gde.2012.02.008 · 2012 · External reference

PRC2 and SWI/SNF Chromatin Remodeling Complex-es in Health and Disease

10.1021/acs.biochem.5b01191 · 2016 · External reference

SWI/SNF nucleosome remodellers and cancer

10.1038/nrc3068 · 2011 · External reference

EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma

10.1158/1541-7786.mcr-14-0034 · 2014 · External reference

No easy way out for EZH2: its pleiotropic, noncanonical effects on gene regulation and cellular function

10.3390/ijms21249501 · 2020 · External reference

Cancer as a dysregulated epigenome allowing cellular growth ad-vantage at the expense of the host

10.1038/nrc3486 · 2013 · External reference

10.1111/liv.12503

10.1111/liv.12503 · External reference

Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma

10.18632/oncotarget.5724 · 2015 · External reference

Oncogenic roles of SMARCB1/INI1 and its deficient tumors

10.1111/cas.13173 · 2017 · External reference

10.1371/journal.pone.0331118

10.1371/journal.pone.0331118 · External reference

EZH2 expression in hepatocellular carcinoma and its rela-tionship with circadian rhythm-related genes

10.1038/s41598-025-26175-x · 2025 · External reference

Clinical value of EZH2 in hepatocellular carcinoma and its potential for target therapy

10.3390/medicina58020155 · 2022 · External reference

Stage-dependent EZH2 methylation cor-relates with immune polarization, metabolic suppression, and unfavorable outcomes in hepatocellular carcinoma

10.7150/ijms.119496 · 2025 · External reference

Knockdown of CTCF reduces the binding of EZH2 and affects the methylation of the SOCS3 promoter in hepatocellular carcinoma

10.1016/j.biocel.2020.105685 · 2020 · External reference

Epigenetically modulated miR-1224 suppresses the prolifera-tion of HCC through CREB-mediated activation of YAP signaling pathway

10.1016/j.omtn.2021.01.008 · 2021 · External reference

Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepa-tocarcinogenesis

10.1016/j.canlet.2021.10.039 · 2022 · External reference

Integrated single-cell RNA-seq analysis reveals that EZH2 regulates the MIF-CD74 axis to modulate T cell activation and exhaustion in hepatocellular carcino-ma

10.1186/s12967-025-07071-4 · 2025 · External reference

Glutamate promotes CCL2 expression to recruit tumor-associated macrophages by restraining EZH2-mediated histone methylation in hepatocellu-lar carcinoma

10.1080/2162402x.2025.2497172 · 2025 · External reference

Identifying key genes involved in HBV-related hepato-cellular carcinoma: diagnose, prognosis, interaction and immune analysis

10.1007/s12672-025-03320-6 · 2025 · External reference

Construction of an oxidative stress risk model to analyze the corre-lation between liver cancer and tumor immunity

10.2174/0115680096284532231220061048 · 2025 · External reference

SMARCB1/INI1 is diagnostically useful in distinguish-ing α-fetoprotein-producing gastric carcinoma from hepatocellular carcinoma

10.21873/anticanres.13061 · 2018 · External reference

Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib

10.2217/epi-2021-0383 · 2022 · External reference

1/VIPR1 axis may suppress the develop-ment of hepatocellular carcinoma: a bioinformatics analysis and experimental validation

10.1186/s12967-022-03573-7 · 2022 · External reference